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S202 Poster Session Ichildren’s parents. Unlike public banks, which utilize specific criteria
for banking, private banks generally store any collected unit regard-
less of size or cell content.
Methods: Patients with neurological disorders with banked aCB
were self-referred or referred by their treating physicians. CB
units (CBU) containing .110e7 cells/kg were shipped to Duke
from the banks of origin after confirming identity by HLA typing.
Viability was confirmed on a test sample when available. CBUs,
50% stored in bags and 50% in vials, were thawed and washed
in the standard fashion. Patients were premedicated with Tylenol,
Benadryl and Solumedrol prior to infusion and monitored for
4 hours. Data about patients, infusions and CBUs were collected
retrospectively. Characteristics of CBUs were compared to exist-
ing data from CBUs publicly banked at the Carolinas Cord Blood
Bank.
Results:From 3/2004 to 8/2009, 154 children with neurological dis-
orders (78% cerebral palsy, 13% congenital hydrocephalus, 9%
other injuries) received 164 aCB infusions. Median age at infusion
was 2 yrs (range 6 days–9 yrs). One patient had an anaphylactic infu-
sion reaction which responded to medical therapy and stopping the
infusion. Mean pre-cryopreservation volume (66.2 vs 97.6 ml,
p\0.001), TNC (12.3 vs 15.510e8, p\0.001), and CD34 (3.0
vs 4.110e6, p5 0.004) were significantly lower than publicly stored
CBUs. Post thaw sterility cultures were positive in 6.5% of CBUs in-
fused versus 0.5% of publicly stored units. Post thaw recoveries of
TNC, 3.310e8 (27% pre-cryo TNC), and CD34, 1.2 (40% pre-
cryo CD34), were also lower than expected.
Conclusions: IV infusion of aCB is safe and feasible in young chil-
dren with neurological conditions. The overall quality parameters of
privately banked UCBs was inferior to those stored in public banks.
If evidence for efficacy of aCB is established clinically, the quality of
aCB units should be held to the same standards as those stored in
public banks.120
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Background: Hyper-CVAD (fractionated cyclophosphamide, vin-
cristine, doxorubicin and dexamethasone combined with high
doses of cytarabine and methotrexate) is an intense chemotherapy
regimen frequently used as front line therapy for a number of he-
matologic malignancies including mantle cell lymphoma. It has
been observed anecdotally that patients with mantle cell lym-
phoma who have been treated with hyper-CVAD have more dif-
ficulty mobilizing sufficient PBSC than those who have been
treated with alternative regimens.
Patients and Methods: To address this question, we retrospec-
tively analyzed mobilization data from 74 consecutive patients
over the age of 18 diagnosed with mantle cell lymphoma who un-
derwent ASCT at the Cleveland Clinic between July, 1996 and
November, 2008. 26 of these patients had previously been treated
with hyper-CVAD and 48 had received alternative regimens (pre-
dominantly CHOP with or without rituximab). Patients treated
with hyper-CVAD were more likely to have undergone mobiliza-
tion with VP16 + G-CSF (VP-G): 92% received VP-G, whereas
only 50% of patients treated with alternative regimens received
VP-G (P5\ 0.001).
Results: Patients treated with hyper-CVAD collected fewer CD34+
stem cells on day 1 (median5 0.43 106 CD34+ cells/kg) compared
to patients treated with alternative regimens (median5 3.00  106,
P5 0.002, see Table). In addition, patients treated with hyper-
CVAD were also more likely to fail in collecting sufficient CD34+
cells during their first mobilization attempt compared to patients
treated with alternative regimens 23.1% vs. 4.2%, P5 0.012). Pa-tients treated with hyper-CVAD underwent a median total of 5
days of pheresis vs. 3 days for patients treated with alternative regi-
mens (P5 0.019).
Conclusions: Compared to patients treated with alternative regi-
mens, patients with mantle cell lymphoma treated with hyper-
CVAD were more likely to undergo mobilization with a VP16-con-
taining regimen yet still collected fewer CD34+ cells (day 1, day 2,
days 1 + 2, and total), required more total days of pheresis, and
more frequently required a second mobilization attempt. These re-
sults suggest a potential role of alternative mobilizing strategies in
patients with mantle cell lymphoma as an adjuvant to standard prim-
ing regimens in order to improve mobilization of PBSC prior to
ASCT.
Table. Mobilization Results
Hyper-CVAD (N5 26) Alternative Regimens (N5 48)CharacteristicMedian
(range) (Number
percent)Median
(range)Number
(percent) PCD341 cells
collected on
day 1 (x 106/kg)0.43
(0.09-13.33)3.00
(0.02-60.36)0.002CD341 cells
collected on day
2 (x 106/kg)0.62
(0.09-12.88)2.65
(0.11-29.16)0.008Total CD341 cells
collected
(x 106/kg)4.13
(2.11-27.88)8.92
(2.06-89.52)0.037Total days of
pheresis5 (2-11) 3 (2-10) 0.019Number of
patients who
failed to collect
sufficient CD341
cells during first
mobilization
attempt6 (23.1%) 2 (4.2%) 0.012121
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Objectives: Autologous SCM is usually done using myelosuppres-
sive chemotherapy plus G-CSF (G), which is considered safe and ef-
fective, but exposes patients (pts) to risks and side effects. To better
understand the comparative effectiveness of standard and newer
treatments for SCM, the aims of study were: (1) clinical outcomes
and cost consequences of cyclophophamide (CY) plus G SCM (2)
to compare outcomes of CY + G to a clinical trial of plerixafor
(P)+G.
Methods: A retrospective study was conducted in all patients un-
dergoing first SCM from 1/04 to 3/08 (N5 241) with CY (3
gm/m2) and G (10 mcg/kg started day after CY for 10 days with
a planned first day of collection on day 11) and pheresis initiated
when peripheral blood had .15 CD34+ cells/uL. Positive clinical
outcome (PCO) was defined as .2106 CD34+ cells/kg collected
on planned day of collection in 1 or 2 apheresis without a prior
negative event that led to additional clinic/inpatient evaluation.
The cost of drugs, pheresis, product processing, and clinical events,
were reported based on Medicare part B physician, laboratory, and
ancillary fee schedule. Data on pts undergoing SCM with P + G
were obtained from a published clinical trial in pts with myeloma
